JAK1 and neoplasm: Lastly, we examined the frequency of somatic copy number alterations (SCNA) associated with regulation of anti-tumor immune responses in pre-clinical and clinical studies: gains in MYC16, losses of PTEN17 and gains or losses in interferon pathway genes (PDCD1, STAT1, JAK1, and JAK2) (Fig. 2A).